

UNIVERSITAT DE

BARCELONA

#8P; First decision impact study of HER2DX in patients with HER2-positive early breast cancer

Martínez-Sáez O^{1,2}, Brasó-Maristany F², Marín Aguilera M³, Vidal M^{1,2}, Adamo B^{1,2}, Pascual T^{1,2}, Schettini F^{1,2}, Conte B^{1,2}, Chic N^{1,2}, Gómez-Bravo R^{1,2}, Garcia-Fructuoso I^{1,2}, Seguí Solís E^{1,2}, Galván P, Hernández-Illán E⁴, Jares P⁴, Puig-Butille A⁴, Sanfeliu E^{2,5}, Brunet L³, Villagrasa González P³, Muñoz M^{1,2}

¹Medical Oncology Dept, Hospital Clínic, Barcelona, Spain; ²Institut D'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain; ³Scientific Dept, Reveal Genomics, S.L., Barcelona, Spain; ⁴Molecular Biology Core, Biochemistry and Molecular Genetics Department, Hospital Clinic, Barcelona, Spain; ⁵Pathology department, Hospital Clinic, Barcelona, Spain.

Background and objectives

 HER2DX is a genomic test based on the expression of 27 genes tracking 4 signatures (luminal, proliferative, immune and HER2 amplicon) (Figure 1) that provides prognostic (HER2DX risk score) and predictive information (HER2DX pathologic complete response [pCR] score) in HER2 positive (HER2+) early breast cancer (BC). Here, we report the initial results of the first ongoing decision impact study of HER2DX at Hospital Clinic of Barcelona.

Figure 1. HER2DX components.



Methods

- This is an ongoing observational, prospective, pilot, unicentric study, since Nov/2021 (Figure 2), to analyze the impact of HER2DX in clinical practice in early-stage HER2+ BC. Any medical oncologist of the Breast Unit could order the test (11 oncologist participated). A survey was completed by the treating physician before and after receiving the result of HER2DX.
- The main objective was to assess the % of change in the therapeutic plan after obtaining the HER2DX report.
- Secondary objectives included 1) assess changes in the physician's confidence before and after the test in a scale from 1 to 5 (1 being the lowest confidence a 5 the maximum) and 2) analyze the association of the HER2DX pCR-score with the pathological response after neoadjuvant therapy (NAT).
- Descriptive statistics were used.

Figure 2. Study design.

Prospe

Nov/21

HER Sta

línic arcelona		[
tive study – Present			HER2DX	
BC pts	N = 89			
ge I-III		Pre-test questionnaire		 Post-test questionnarie

Table 1. Baseline characteristics of patients.

	All (N = 89)	HER2DX High risk (n = 44)	HER2DX Low risk (n = 45)	р
Histology– no. (%) Ductal Lobulillar Apocrine Micropapilar Neuroendocrine	77 (87%) 4 (4%) 4 (4%) 3 (3%) 1 (1%)	37 (84%) 3 (7%) 1 (2%) 2 (5%) 1 (2%)	40 (89%) 1 (2%) 3 (7%) 1 (2%) 0	0.636
Menopausal status – no. (%) Premenopausal Postmenopausal Unknown	42 (47%) 46 (52%) 1 (1%)	25 (57%) 18 (41%) 1 (2%)	17 (38%) 28 (62%)	0.083
cT – no.(%) T1 T2 T3 T4	42 (6%) 35 (40%) 9 (10%) 3 (3%)	13 (30%) 20 (45%) 8 (18%) 3 87%)	29 (64%) 15 (33%) 1 (2%) 0	0.004
cN – no. (%) No N1 N2 N3	57 (64%) 27 (30%) 2 (2%) 3 (3%)	14 (32%) 25 (57%) 2 (5%) 3 (7%)	43 (96%) 2 (4%) 0 0	< 0.001
Hormone receptor – no.(%) Positive Negative Unknown	58 (65%) 29 (33%) 2 (2%)	30 (68%) 13 (30%) 1 (2%)	28 (62%) 16 (36%) 1 (2%)	0.602
Ki67 Median (range)	35 (4 - 90)	35 (4 - 90)	33 (8 - 75)	0.627
TILs Median (range)	10 (0 - 90)	5 (0 - 60)	15 (0 - 90)	0.034
Grade – no. (%) G1 G2 G3	3 (4%) 45 (56%) 33 (41%)	1 (3%) 23 (58%) 16 (40%)	2 (5%) 22 (54%) 17 (42%)	0.870

Principal objective: % of change in the intention of the treatment plan

Results

89 patients (pts) have been recruited until 2nd of Feb/2023. Median age was 53 years (range 30-79) and 52% of pts were postmenopausal. Most pts had T1-2 tumors (87%), negative nodes (64%), grade 2 (56%) or 3 (41%), ductal histology (87%), hormone receptor positive (65%), median Ki67 of 35% (range 4-90%) and median tumor-infiltrating lymphocytes of 10% (range 0-90%) (**Table 1**).


78% of pts received NAT and 22% were treated with upfront surgery.

- 87 (56%) cases (**Figure 4**).
- The confidence in the decision improved in 67% of cases.
- type of therapy (**Figure 6**).

Figure 3. Example of HER2DX results report.



Figure 4. Decision change.








Results

• A change in the treatment plan before and after the HER2DX result (Figure 3) was observed in 49 of

• De-escalation of therapy was observed in 59% of pts (less intense chemotherapy [ChT] in 57% of them) and escalation in 41% of pts (more intense ChT in 65% of them).

• Among 56 evaluable pts treated with NAT, HER2DX pCR score was significantly associated with pCR (81% in pCR-medium/high and 32% in pCR-low; odds ratio= 9.3, p= 0.001) (Figure 5), independently of

Figure 5. pCR according to HER2DX pCR score group.



HER2DX pCR-score group

Figure 6. Neoadjuvant treatment by pCR score group.

	pCR score Med/High (n = 37)	pCR score Low (n = 19)	р
Dual HER2 blockade – no. (%)	34 (92%)	17 (89%)	0.557
Multi-agent ChT – no. (%)	27 (73%)	12 (63%)	0.323

Conclusions

In this first pilot and prospective study, HER2DX impacted clinical care in early-stage HER2+ breast cancer.

pts (59%)

pts (41%)

Conflicts of interest: OM has declared travel expenses and consulting fees from Roche and Reveal, and speaker fees from Eisai, Daiichi and Novartis.

his presentation is the intellectual property of the author/presenter. Contact them at olmartinez@clinic.ca for permission to reprint and/or distribute